Literature DB >> 11887432

Impact of obesity in primary hyperlipidemias.

R Carmena1, J F Ascaso, J T Real.   

Abstract

Obesity is frequently associated with high plasma triglyceride and reduced plasma high-density lipoprotein (HDL)-cholesterol (HDL-C) levels, and an increased concentration of apoB-carrying lipoproteins. The effects of obesity on lipid metabolism are mainly mediated by insulin resistance and, as central (visceral) obesity significantly increases insulin resistance, it aggravates these lipid changes. We have reviewed the impact of obesity on lipid metabolism in different types of primary hyperlipidemias. Obesity is not common in primary (familial and polygenic) hypercholesterolemias, and insulin resistance is infrequent; various investigators have found no or only a weak association between plasma cholesterol concentrations and insulin levels. On the other hand, in familial hypertriglyceridemia (type IV) and familial combined hyperlipidemia (FCH), obesity and insulin resistance are common and, when present, contribute to a further deterioration in the lipid profile. Weight loss in most of these patients is accompanied by a significant decrease in plasma triglyceride levels and an increase in HDL-C. Reviewing the data published by our group, we show that insulin resistance is an important component of the metabolic derangement in FCH subjects; high fasting plasma free fatty acids and triglycerides levels correlate to insulin resistance, thus linking this abnormality to lipid metabolism. A high waist/hip ratio (indicating visceral fat deposits) exacerbates insulin resistance, but this is also present in lean FCH subjects. Furthermore, insulin resistance is associated with a higher prevalence of coronary heart disease in this group of subjects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11887432

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  4 in total

Review 1.  A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies.

Authors:  Adrian Bagust; Marc Evans; Sophie Beale; Philip D Home; Andrew S Perry; Murray Stewart
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Changes in fitness and fatness on the development of cardiovascular disease risk factors hypertension, metabolic syndrome, and hypercholesterolemia.

Authors:  Duck-Chul Lee; Xuemei Sui; Timothy S Church; Carl J Lavie; Andrew S Jackson; Steven N Blair
Journal:  J Am Coll Cardiol       Date:  2012-02-14       Impact factor: 24.094

3.  The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile.

Authors:  Ping Wang; Marleen M J van Greevenbroek; Freek G Bouwman; Martijn C G J Brouwers; Carla J H van der Kallen; Egbert Smit; Jaap Keijer; Edwin C M Mariman
Journal:  Pflugers Arch       Date:  2007-04-12       Impact factor: 3.657

4.  Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation.

Authors:  Laurence Hoareau; Régis Roche; Ravi Murumalla; Karima Bencharif; Lydie Gence; Amritendu Bhattacharya; Frank Tallet; Marie-Paule Gonthier; Stefania Petrosino; Vincenzo di Marzo; Maya Cesari
Journal:  J Inflamm (Lond)       Date:  2011-11-16       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.